New Factor XIa Inhibitor Cuts Stroke Risk With Lower Bleeding: Phase III Win
Alex So, Associate Director Strategy and Digitalisation China at Merck Group, posted on LinkedIn:
”Rather than a discouraging attempt that the quoted video may suggest, it is delightful to know the factor XIa inhibitor’s potential to reduce stroke risk in patients who have had a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, as reported by its latest phase III trial for secondary stroke prevention.
Factor XIa can activate Factor IX, amplifying thrombin generation of the clotting process. As an anticoagulation strategy, the inhibition has less impact on clot stabilisation in response to injury, i.e., a lower risk of bleeding. It might be worth rementioning the siRNA drug that silences the gene producing antithrombin, a mechanism in this field applicable to haemophilia as discussed in a prior post.
The milestone success, which enables continued efforts to develop a better blood thinner despite a somewhat reduced scope and to investigate Factor XIa as a target, is encouraging.
Non-business-related therapeutics posting. Consult practitioners for medication needs.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS